Valuation SCYNEXIS, Inc.

Stocks

Market Closed - Nasdaq Other stock markets 00:00:00 24/07/2026 +04			5-day change	1st Jan Change
3.960 ^USD	+0.13%		-11.61%	-21.73%

06-30	SCYNEXIS, Inc. Initiates Phase 1 Study of SCY-770 for Treatment of Autosomal Dominant Polycystic Kidney Disease	CI
06-30	Scynexis Initiates Phase 1 Study of SCY-770 to Treat Autosomal Dominant Polycystic Kidney Disease	MT

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	174	50.94	82.97	45.92	26.54	39.32	-	-
Change	-	-70.72%	62.87%	-44.66%	-42.2%	48.18%	-	-
Enterprise Value (EV)	174	50.94	82.97	45.92	26.54	39.32	39.32	39.32
Change	-	-70.72%	62.87%	-44.66%	-42.2%	48.18%	0%	0%
P/E	-4.88x	-1.06x	1.6x	-2.75x	-3.72x	-0.97x	-1.57x	-2.52x
PBR	-	-	-	-	-	-	-	-
PEG	-	-0.1x	-0x	0x	0.1x	-0x	0x	0.1x
Capitalization / Revenue	13.2x	10x	0.59x	12.3x	1.29x	34.1x	5.89x	2.79x
EV / Revenue	0x	0x	0x	0x	0x	34.1x	5.89x	2.79x
EV / EBITDA	-	-	-	-	-	-	-	-
EV / EBIT	-0x	-0x	0x	-0x	-0x	-1.2x	-1.76x	-2.07x
EV / FCF	-	-	-	-	-	-	-	-
FCF Yield	-	-	-	-	-	-	-	-
Dividend per Share ²	-	-	-	-	-	-	-	-
Rate of return	-	-	-	-	-	-	-	-
EPS ²	-10	-11.76	11.12	-3.52	-1.36	-4.08	-2.52	-1.573
Distribution rate	-	-	-	-	-	-	-	-
Net sales ¹	13.16	5.091	140.1	3.746	20.6	1.154	6.677	14.08
EBITDA	-	-85.15	-	-	-	-	-	-
EBIT ¹	-60.84	-85.76	72.67	-37.12	-16.07	-32.73	-22.4	-19.04
Net income ¹	-32.87	-62.81	67.04	-21.29	-8.609	-41.07	-28.73	-18.64
Net Debt	-	-	-	-	-	-	-	-
Reference price ²	48.800	12.480	17.840	9.680	5.059	3.960	3.960	3.960
Nbr of stocks (in thousands)	3,565	4,082	4,651	4,744	5,246	9,930	-	-
Announcement Date	29/03/22	31/03/23	28/03/24	12/03/25	04/03/26	-	-	-

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (N)	EV / Sales (N)	EV / EBITDA (N)	Dividend Yield (N)	Capi.($)
SCYNEXIS, INC.	-0.97x	-	-	-	39.32M
ELI LILLY AND COMPANY	35.39x	12.58x	26.43x	0.57%	1,057B
JOHNSON & JOHNSON	27.79x	6.35x	17.58x	2.07%	624B
ABBVIE INC.	33.47x	7.59x	15.59x	2.68%	454B
ROCHE HOLDING AG	20.98x	4.63x	11.4x	2.86%	341B
NOVARTIS AG	21.62x	5.7x	13.97x	2.82%	297B
ASTRAZENECA PLC	21.08x	4.45x	12.3x	1.98%	262B
NOVO NORDISK A/S	14.13x	5.26x	10.83x	3.54%	215B
AMGEN INC.	24.37x	6.41x	11.32x	2.71%	201B
GILEAD SCIENCES, INC.	-47.14x	5.65x	31.2x	2.52%	162B
Average	15.07x	6.51x	16.74x	2.42%	361.4B
Weighted average by Cap.	24.72x	7.88x	18.52x	1.98%